Topics

Cancer Genetics settles failed merger with NovellusDx

06:35 EDT 28 Oct 2019 | SmartBrief

Cancer Genetics has settled its failed merger deal with NovellusDx, paying $1.1 million in cash and $450,000 over nine months -More

Original Article: Cancer Genetics settles failed merger with NovellusDx

NEXT ARTICLE

More From BioPortfolio on "Cancer Genetics settles failed merger with NovellusDx"

Quick Search

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...